Trials / Completed
CompletedNCT03598790
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,353 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
Detailed description
The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-specified time-points. |
Timeline
- Start date
- 2018-09-05
- Primary completion
- 2023-11-14
- Completion
- 2023-11-14
- First posted
- 2018-07-26
- Last updated
- 2026-04-15
- Results posted
- 2024-12-06
Locations
189 sites across 13 countries: United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russia, South Korea, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03598790. Inclusion in this directory is not an endorsement.